Status:
COMPLETED
Does Rosuvastatin Delay Progression of Atherosclerosis in HIV
Lead Sponsor:
Bayside Health
Conditions:
HIV
Cardiovascular Disease
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
This study is a randomised double blind placebo controlled trial comparing Rosuvastatin with placebo in HIV positive people who are at intermediate cardiovascular risk. It is possible that HIV positi...
Detailed Description
Participants will be randomised to receive either the active agent (Rosuvastatin) or a placebo once daily for 96 weeks. Participants will undergo blood tests and ultrasounds of the arteries of the ne...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Moderate cardiovascular disease (CVD) risk, (10-15% 10 year risk of CVD)
- HIV positive
- Stable combination anti-retroviral therapy (cART) with plasma HIV viral load \<200copies/ml for ≥ 6 months
Exclusion
- Recommended use of lipid lowering therapy according to Australian guidelines
- Prior use of statin, fibrate, ezetimibe within the last six months
- Contraindication to statin use
Key Trial Info
Start Date :
July 2 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01813357
Start Date
July 2 2013
End Date
November 1 2018
Last Update
August 28 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3004
2
Hospitaux Universitaires de Geneve
Geneva, Switzerland